Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Personalis, Inc.

< Previous 1 2 3 4 Next >
Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Appoints Christopher Hall as Chief Executive Officer
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Reports Fourth Quarter and Full Year 2022 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
From Personalis, Inc.
Via Business Wire
Tickers MRNA PSNL
Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces CEO Retirement and Transition
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Cancer Assay NeXT Personal Ranks #1 on The Scientist’s Top 10 Innovations of 2022
From Personalis, Inc.
Via Business Wire
Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Present at the 34th Annual Piper Sandler Healthcare Conference
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Reports Third Quarter 2022 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Grows Leadership Team with Appointment of Christopher Hall as Senior Vice President and Head, Diagnostics Business
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Announce Third Quarter 2022 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight Diagnostics
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Reports Second Quarter 2022 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Files Patent Infringement Lawsuit Against Foresight Diagnostics
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Announce Second Quarter 2022 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Expansion of Its Patent Portfolio Related to Tumor-Informed Detection of Molecular Residual Disease
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Reports First Quarter 2022 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Present at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
Tickers PSNL
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.